Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7203487 | 1.00 | CTSK (0.40) | CTSKPKMDRD4 | |
| SCHEMBL5575176 | 0.94 | CTSK (0.40) | CTSKPKM | |
| SCHEMBL6899315 | 0.92 | CTSK (0.41) | CTSKPKMDRD4 | |
| SCHEMBL4687353 | 0.85 | CTSK (0.52) | CTSKPKMDRD4 | |
| SCHEMBL5096677 | 0.85 | CTSK (0.52) | CTSKPKMDRD4 | |
| SCHEMBL4687256 | 0.82 | CTSK (0.38) | CTSKPKM | |
| SCHEMBL4686550 | 0.82 | CTSK (0.43) | CTSK | |
| SCHEMBL5949076 | 0.77 | CTSK (0.33) | CTSKPKM | |
| SCHEMBL4686403 | 0.77 | CTSK (0.54) | CTSKPKMDRD4 | |
| SCHEMBL4315397 | 0.76 | CTSK (0.38) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1351930-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-09-15 | — | — | EP | claimed |
| EP-1351930-A2 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-10-15 | — | — | EP | claimed |
| US-6583137-B1 | Cysteine proteases, particularly cathespin K, inhibition of bone loss, cartilage degradation; quinoxaline-2-carboxylic acid ((S)-3-methyl-1-((2,2',4-trideuterio)-3-oxo-1-(1-oxy-pyridine-2-sulfonyl) -azepan-4-ylcarbamoyl)-butyl)amide) | SMITHKLINE BEECHAM CORPORATION | 2003-06-24 | — | — | US | claimed |
| WO-2001034566-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | claimed |
| EP-1232154-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-06-23 | — | — | EP | disclosed |
| US-6596715-B1 | Pharmaceutically acceptable salt, hydrate or solvate thereof, which is an inhibitor of cysteine proteases, particularly cathepsin K, and is useful in the treatment of diseases in which inhibition of bone loss or of cartilage degradation is a | SMITHKLINE BEECHAM CORPORATION | 2003-07-22 | — | — | US | disclosed |
| US-6583137-B1 | Cysteine proteases, particularly cathespin K, inhibition of bone loss, cartilage degradation; quinoxaline-2-carboxylic acid ((S)-3-methyl-1-((2,2',4-trideuterio)-3-oxo-1-(1-oxy-pyridine-2-sulfonyl) -azepan-4-ylcarbamoyl)-butyl)amide) | SMITHKLINE BEECHAM CORPORATION | 2003-06-24 | — | — | US | disclosed |
| EP-1229911-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-05-07 | — | — | EP | disclosed |
| EP-1232155-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-11-20 | — | — | EP | disclosed |
| EP-1232154-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2002-08-21 | — | — | EP | disclosed |
| EP-1232155-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2002-08-21 | — | — | EP | disclosed |
| EP-1229911-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001034599-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034600-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034153-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |